Amarin suffers defeat over Vascepa patents
A US judge has opened the door to generic versions of heart disease drug Vascepa, after invalidating Amarin’s key patents covering the drug.
Gilead expands special access to potential COVID-19 drug
Gilead Sciences says it is expanding access to its experimental antiviral remdesivir for treatment of COVID-19, albeit on a limited basis.
Associations lobby WHO to build COVID-19 IP pool
Numerous associations and individuals have come together to ask the World Health Organization to build a global pool for IP rights related to the COVID-19 pandemic.
Canada authorises compulsory licences for COVID-19 shortfalls
Canada is the latest country to adopt emergency measures in order to secure drugs and medical equipment in the fight against COVID-19.
Novartis and others in ‘unprecedented’ COVID-19 partnership
A consortium of life sciences companies including Novartis, Bristol Myers Squibb and GSK have united to accelerate the development, manufacture and delivery of vaccines, diagnostics, and treatments for COVID-19.
Gilead backs away from antiviral monopoly after criticism
Gilead Sciences has agreed to drop the lucrative “orphan drug” designation for an antiviral touted as a potential coronavirus treatment, after criticism from activists and politicians including Bernie Sanders.
Abbott scores case-ending sanctions against wholesaler
Medical device maker Abbott has secured a series of case-ending sanctions against a wholesaler, bringing the five-year-long dispute to a close.
Webinar: Plenty to fight for in CRISPR IP battle
Despite a recent swing in momentum to the University of California, it’s still too early to say who is likely to emerge triumphant in the CRISPR patent battle.
Costa Rica asks WHO to create voluntary COVID-19 IP pool
The Costa Rican government has asked the World Health Organization to create a voluntary pool to collect patent rights for technologies that are useful for the detection, prevention, control and treatment of the COVID-19 pandemic.
US companies hit hardest by fake medicines: EUIPO, OECD
Companies registered in the US are hit hardest by the trade in counterfeit medicines, which in 2016 reached $4.4 billion, according to a report from the European Union Intellectual Property Office.
